136 related articles for article (PubMed ID: 38159411)
21. Nicotine promotes blood retinal barrier damage in a model of human diabetic macular edema.
Maugeri G; D'Amico AG; Rasà DM; La Cognata V; Saccone S; Federico C; Cavallaro S; D'Agata V
Toxicol In Vitro; 2017 Oct; 44():182-189. PubMed ID: 28689815
[TBL] [Abstract][Full Text] [Related]
22. AQUEOUS HUMOR CYTOKINE LEVELS AND REBOUND MACULAR EDEMA AFTER CONBERCEPT TREATMENT IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION.
Yang KB; Sun XY; Sun LP; Li J; Liu ZL; Zhang H
Retina; 2021 Apr; 41(4):834-843. PubMed ID: 33755650
[TBL] [Abstract][Full Text] [Related]
23. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy.
Zhang SX; Wang JJ; Gao G; Parke K; Ma JX
J Mol Endocrinol; 2006 Aug; 37(1):1-12. PubMed ID: 16901919
[TBL] [Abstract][Full Text] [Related]
24. Aqueous humor inflammatory cytokine levels and choroidal thickness in patients with macular edema associated with branch retinal vein occlusion.
An Y; Park SP; Kim YK
Int Ophthalmol; 2021 Jul; 41(7):2433-2444. PubMed ID: 33740201
[TBL] [Abstract][Full Text] [Related]
25. Pathophysiology of macular edema.
Scholl S; Kirchhof J; Augustin AJ
Ophthalmologica; 2010; 224 Suppl 1():8-15. PubMed ID: 20714176
[TBL] [Abstract][Full Text] [Related]
26. Müller glial cells--the mediators of vascular disorders with vitreomacular interface pathology in diabetic maculopathy.
Robaszkiewicz J; Chmielewska K; Figurska M; Wierzbowska J; Stankiewicz A
Klin Oczna; 2010; 112(10-12):328-32. PubMed ID: 21469528
[TBL] [Abstract][Full Text] [Related]
27. Plasmalemma Vesicle-Associated Protein Has a Key Role in Blood-Retinal Barrier Loss.
Wisniewska-Kruk J; van der Wijk AE; van Veen HA; Gorgels TG; Vogels IM; Versteeg D; Van Noorden CJ; Schlingemann RO; Klaassen I
Am J Pathol; 2016 Apr; 186(4):1044-54. PubMed ID: 26878208
[TBL] [Abstract][Full Text] [Related]
28. Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema.
Noma H; Yasuda K; Shimura M
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810434
[TBL] [Abstract][Full Text] [Related]
29. Pentraxin 3 and other inflammatory factors in central retinal vein occlusion and macular edema.
Noma H; Mimura T; Masahara H; Shimada K
Retina; 2014 Feb; 34(2):352-9. PubMed ID: 23842103
[TBL] [Abstract][Full Text] [Related]
30. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha.
Forooghian F; Das B
Am J Ophthalmol; 2007 Nov; 144(5):761-8. PubMed ID: 17869204
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.
Amin RH; Frank RN; Kennedy A; Eliott D; Puklin JE; Abrams GW
Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):36-47. PubMed ID: 9008628
[TBL] [Abstract][Full Text] [Related]
32. Pigment epithelium-derived factor inhibits vascular endothelial growth factor-and interleukin-1beta-induced vascular permeability and angiogenesis in retinal endothelial cells.
Sheikpranbabu S; Ravinarayanan H; Elayappan B; Jongsun P; Gurunathan S
Vascul Pharmacol; 2010; 52(1-2):84-94. PubMed ID: 20006737
[TBL] [Abstract][Full Text] [Related]
33. NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression.
D'Amico AG; Maugeri G; Rasà DM; La Cognata V; Saccone S; Federico C; Cavallaro S; D'Agata V
J Cell Physiol; 2018 Feb; 233(2):1120-1128. PubMed ID: 28436035
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier.
Saishin Y; Saishin Y; Takahashi K; Melia M; Vinores SA; Campochiaro PA
J Cell Physiol; 2003 May; 195(2):210-9. PubMed ID: 12652648
[TBL] [Abstract][Full Text] [Related]
35. Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy.
Tang L; Xu GT; Zhang JF
Neural Regen Res; 2023 May; 18(5):976-982. PubMed ID: 36254977
[TBL] [Abstract][Full Text] [Related]
36. Bone morphogenetic protein 2: a potential new player in the pathogenesis of diabetic retinopathy.
Hussein KA; Choksi K; Akeel S; Ahmad S; Megyerdi S; El-Sherbiny M; Nawaz M; Abu El-Asrar A; Al-Shabrawey M
Exp Eye Res; 2014 Aug; 125():79-88. PubMed ID: 24910902
[TBL] [Abstract][Full Text] [Related]
37. Pathomechanisms of cystoid macular edema.
Bringmann A; Reichenbach A; Wiedemann P
Ophthalmic Res; 2004; 36(5):241-9. PubMed ID: 15583429
[TBL] [Abstract][Full Text] [Related]
38. Cytokine Kinetics after Monthly Intravitreal Bevacizumab for Retinal Vein Occlusion Associated with Macular Oedema.
Noma H; Mimura T; Yasuda K; Shimura M
Ophthalmic Res; 2016; 56(4):207-214. PubMed ID: 27160159
[TBL] [Abstract][Full Text] [Related]
39. Expressions of HIF-1α and MiR-210 in aqueous humor of patients with central retinal vein occlusion combined with macular edema.
Hu P; Liu G; Sun H; Wei W
Pak J Med Sci; 2022; 38(5):1327-1332. PubMed ID: 35799735
[TBL] [Abstract][Full Text] [Related]
40. Association of vitreous inflammatory factors with diabetic macular edema.
Funatsu H; Noma H; Mimura T; Eguchi S; Hori S
Ophthalmology; 2009 Jan; 116(1):73-9. PubMed ID: 19118698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
